|
|
|
| The application of drug-coated balloon in in situ and long lesions of large vessels in coronary arteries |
| YAN Xigui1, PENG Huaiming2, ZHENG Yong1, HUANG Chunping3, LIU Wenmin1, YANG Deye1. |
| 1.Department of Cardiology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China; 2.Department of Respiratory, People’s Hospital of Tinghu, Yancheng 224001, China; 3.Hangzhou Center for Disease Control and Prevention, Hangzhou 310015, China |
|
| Cite this article: |
|
YAN Xigui,PENG Huaiming,ZHENG Yong, et al. The application of drug-coated balloon in in situ and long lesions of large vessels in coronary arteries[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(8): 625-631.
|
|
|
Abstract Objective: To observe the efficacy of drug-coated balloon (DCB) in the treatment of large vessels in situ (reference diameter≥2.8 mm) and in situ long lesions (reference diameter≥2.8 mm, length≥20 mm) of large vessels in coronary arteries. Methods: A total of 80 patients who were diagnosed and treated in the Department of Cardiology, Affiliated Hospital of Hangzhou Normal University from April 2015 to December 2020 were selected, who were all treated with DCB for in situ primary coronary artery lesions. Computer quantitative coronary angiography analysis software was used to analyze the coronary angiography images of the included patients at three different times: before operation, immediately after operation and follow-up. The selected patients were divided into two groups according to the length of target vessel lesions, namely the lesion length <20 mm group (n=45) and the lesion length≥20 mm group (n=35). The inter-group comparison was performed to evaluate the efficacy of DCB in long in situ coronary artery lesions. Results: The average length of target vessel lesion of the included cases was (15.71±5.98) mm, and the reference diameters was (3.22±0.34) mm. During the follow-up of (15.89±9.34) months, no patients had acute myocardial infarction or severe arrhythmia, cardiogenic
death or stroke. There were no cases of revascularization of target vessel in all follow-up patients, and the late lumen loss during follow-up was (-0.01±0.26) mm. There was no significant difference in late lumen loss between the two groups of patients with different lesion lengths [(0.003±0.3) mm vs. (-0.03±0.23) mm, P=0.615].
Conclusion: DCB is safe and effective in the treatment of in situ and long lesions of large vessels in coronary arteries and it can reduce the late lumen loss of coronary target lesions.
|
|
Received: 11 April 2022
|
| |
|
|
|
|
|
|
